This inventor holds 12 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignee: Biomarin Pharmaceutical Inc.. Active years: 2012-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Mill Valley, CA (US) (2012 - 2018)
- Novato, CA (US) (2017 - 2022)
Company Filing History:
Years Active: 2012-2022
Title: **Innovator Spotlight: Mika Aoyagi-Scharber**
Introduction
Mika Aoyagi-Scharber is an accomplished inventor based in Novato, California, who has made significant contributions to the field of biotechnology. With a total of 12 patents to her name, her work focuses primarily on therapeutic applications, particularly in the treatment of lysosomal storage diseases and other related disorders.
Latest Patents
Among her notable recent innovations are two significant patents. The first patent, titled "Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof," relates to therapeutic fusion proteins designed to treat lysosomal storage diseases through innovative methods. These fusion proteins include components such as a lysosomal enzyme, a lysosomal targeting moiety (such as an IGF-II peptide), and a spacer peptide. This invention plays a vital role in addressing Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome) by utilizing a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu).
Her second patent, titled "Variants of C-type natriuretic peptide," provides CNP variants and pharmaceutical compositions inclusive of these variants. These innovations are essential for treating diseases responsive to CNP, particularly bone-related disorders such as skeletal dysplasias (e.g., achondroplasia) and vascular smooth muscle disorders like restenosis and arteriosclerosis.
Career Highlights
Mika Aoyagi-Scharber is currently associated with BioMarin Pharmaceutical Inc., a leading global biotechnology company that focuses on innovative biopharmaceuticals. Her contributions in the field have not only advanced medical research but have also positively impacted patient care and treatment approaches for various diseases.
Collaborations
In her career, Mika has collaborated with notable colleagues including Daniel J. Wendt and Shinong Long. This collaboration underscores the importance of teamwork in the research and development processes of biopharmaceutical innovations.
Conclusion
Mika Aoyagi-Scharber stands out as a visionary inventor whose patents are paving the way for groundbreaking therapeutic solutions. Her work exemplifies the critical intersection of science and medicine, with a focus on improving the lives of individuals suffering from rare and complex diseases. As she continues to innovate, the impact of her inventions is poised to grow within the biomedical landscape.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile